Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children

NCT04810390 | Completed Phase 3

• 1 other identifier: BOFT-0520/PED
• Study Type: interventional
• Target: 59
• Locations: 1 country
• Sites: 18

Brief Summary

This is a multi-centre, randomised, double blind, placebo-controlled, parallel-group, phase III study to assess the safety, tolerability and efficacy of Bilastine ophthalmic solution 0.6% in children with a documented history of seasonal allergic conjunctivitis (SAC) or perennial allergic conjunctivitis (PAC).

Conditions

Allergic Conjunctivitis

Outcome Measures

Primary Outcomes (1)

• Incidence of related ocular treatment-emergent adverse events (ocular r-TEAEs)

  It will be reported the incidence of related ocular treatment-emergent adverse events (ocular r-TEAEs) as primary safety endpoint.

  8 weeks

Secondary Outcomes (12)

• Incidence of treatment-emergent adverse events (TEAEs)

  8 weeks

• Incidence of ocular treatment-emergent adverse events (ocular TEAEs)

  8 weeks

• Incidence of related treatment-emergent adverse events (r-TEAEs)

  8 weeks

• Incidence of abnormal clinical findings from ophthalmic examinations after instillation of IMP

  8 weeks

• Mean peak ocular discomfort score after on-site instillation of IMP

  8 weeks

Study Arms (2)

Bilastine

EXPERIMENTAL

Daily instillation of one drop in each eye of Bilastine ophthalmic solution 0.6% for 8 weeks.

Drug: Bilastine

Placebo

PLACEBO COMPARATOR

Daily instillation of one drop in each eye of placebo for 8 weeks.

Drug: Placebo

Interventions

Bilastine DRUG

Ophthalmic solution 0.6%

Bilastine

Placebo DRUG

Ophthalmic solution

Placebo

Eligibility Criteria

• Age: 2 Years - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• \. Male or female patients from 2 to under 18 years of age at V1a.
• \. Documented history of AC before V1a.
• \. Documented positive skin prick test and/or positive validated IgE test to seasonal (e.g. grass, ragweed, and/ or tree pollen) and/or perennial allergen (e.g. cat dander, dog dander, dust mites and/ or cockroach) within 6 months before V1a or a positive skin prick test at V1a.
• \. Signs and symptoms of AC, i.e. tearing, itching and redness, that are likely to continue for the next weeks. Minimum score of four (in at least one eye) on an 11-item numeric rating scale in at least one of three categories at V1a.
• \. Understanding of functioning and willingness to use e-diary at V1b and throughout study duration.
• \. Willing to comply in all aspects of the study, including:
• use of IMP from V1b to V5a
• attending scheduled visits and completing telephone interviews.
• \. Signed age-appropriate assent form (in participants 12 years of age and older) and written informed consent by the LAR in all cases. If a patient turns 18 years old during the clinical trial, a new written informed consent form will be provided and signed by the patient if he/she is willing to continue participating in the study.
• \. Be able to self-administer eye drops satisfactorily or have a caregiver or LAR routinely available for this purpose. If a caregiver or LAR will be in charge of administering eye drops then he/she must attend Visit 1b, in order to be trained for administration of eye drops on-site.
• \. For females of childbearing potential only: willingness to perform pregnancy tests, acceptance to use highly effective methods of birth control throughout the study duration. Highly effective methods of birth control include: combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomised partner (provided that partner is the sole sexual partner of the clinical trial participant and has documentation of azoospermia) or sexual abstinence (if defined as refraining from heterosexual intercourse during the entire period of risk associated with the clinical trial treatment). The investigator is responsible for determining whether the subject has adequate birth control for study participation.

You may not qualify if:

• \. History of known contraindications or sensitivities to the use of the IMPs or any of their components.
• \. History of intraocular surgery within the previous 2 years before V1a, or planned surgery during study participation and within 2 weeks after follow-up.
• \. History of ocular trauma (within the previous 6 months before V1a).
• \. History or clinical evidence of ocular herpes simplex or ocular herpes zoster infectious disease within the previous year before V1a.
• \. History of any clinically significant external ocular disease within 30 days before V1a.
• \. Presence of dry eye, active blepharitis, active Meibomian gland dysfunction, active rosacea affecting the ocular surface/ lid margin, active or chronic follicular conjunctivitis, preauricular adenopathy, or any other ocular or periocular abnormality that may affect study outcome at V1a.
• \. Known history of recurrent corneal erosion syndrome (idiopathic or secondary to dry eye).
• \. History of treatment failure to topical antihistamines.
• \. Prior (within 2 years before V1a), current or anticipated anti-allergy immunotherapy.
• \. Prior (within 4 weeks before V1a), current or anticipated corticosteroid treatment (systemic or local, in case of depot-corticosteroids: within 6 weeks before V1a).
• \. Prior (within 1 week before V1a), current or anticipated use of any ophthalmic agents (including artificial tears), except IMPs (starting at V1b).
• \. Wearing of contact lenses 24 hours before ophthalmologic tests (V1a) and during clinical trial participation until V6.
• \. Prior (within 2 weeks before V1a), current or anticipated systemic or intranasal treatment for allergic rhinitis.
• \. Persons committed to an institution by virtue of an order issued either by the judicial or other authorities.
• \. Pregnant woman, breastfeeding woman or woman planning a pregnancy.

Sponsors & Collaborators

• Faes Farma, S.A.: lead
• Dynamic Science S.L.: collaborator

Study Sites (18)

Hospital Universitario de Cruces

Barakaldo, Bizkaia, 48903, Spain

Location

Instituto Oftálmologico Quironsalud A Coruña

A Coruña, Spain

Location

Hospital Universitari German Trias i Pujol (HGTiP),

Badalona, Spain

Location

Hospital Universitari Dexeus

Barcelona, Spain

Location

Hospital Universitari Vall D'Hebron

Barcelona, Spain

Location

Hospital General La Mancha Centro

Ciudad Real, Spain

Location

Clínica Universidad de Navarra (CUN)- Sede Madrid

Madrid, Spain

Location

Hospital Universitario Quirónsalud Madrid

Madrid, Spain

Location

Hospital Quirónsalud Marbella

Marbella, Spain

Location

Hospital Quirónsalud Málaga

Málaga, Spain

Location

Hospital Universitario Central de Asturias

Oviedo, Spain

Location

Clínica Juaneda

Palma de Mallorca, Spain

Location

Clínica Universidad de Navarra

Pamplona, Spain

Location

Hospital Universitario Donostia

San Sebastián, Spain

Location

Hospital de Dia Quirónsalud Ave María

Seville, Spain

Location

Hospital Quirón Valencia

Valencia, Spain

Location

Hospital Universitario Dr. Peset Aleixandre

Valencia, Spain

Location

Hospital Universitario Araba

Vitoria-Gasteiz, Spain

Location

MeSH Terms

Conditions

Conjunctivitis, Allergic

Interventions

bilastine

Condition Hierarchy (Ancestors)

Conjunctivitis; Conjunctival Diseases; Eye Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 1, 2021
• First Posted: March 23, 2021
• Study Start: March 26, 2021
• Primary Completion: November 30, 2022
• Study Completion: November 30, 2022
• Last Updated: March 16, 2023

Record last verified: 2022-07

Locations

ES (18)